Since we proved that GSDME benefited αPD1 therapy by mainly enhancing anti-tumor immunity of CD8+T cells in both mouse models, it could be a representative suitable biomarker for predicting the efficacy of αPD1 no matter what the genotypes of CRC patients are. The gene discussed is CD8A; the disease is colorectal carcinoma.